Announcements Trials
Browse Landscape

Status

Temporarily not available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2544Observational 23Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Locally Advanced Pancreatic Adenocarcinoma 1KRAS G12V Mutant Advanced Epithelial Cancers 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Gemcitabine × Clear all
NCT07319910 2026-01-06

PANOVA-3CA

NovoCure Ltd.

Temporarily not available
Gastrointestinal

Locally Advanced Pancreatic Adenocarcinoma

NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡